{"id":822163,"date":"2025-03-05T16:35:03","date_gmt":"2025-03-05T21:35:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-announces-publication-demonstrating-the-immunogenicity-and-safety-of-its-first-generation-oral-pill-norovirus-vaccine-candidate-in-elderly-adults\/"},"modified":"2025-03-05T16:35:03","modified_gmt":"2025-03-05T21:35:03","slug":"vaxart-announces-publication-demonstrating-the-immunogenicity-and-safety-of-its-first-generation-oral-pill-norovirus-vaccine-candidate-in-elderly-adults","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-announces-publication-demonstrating-the-immunogenicity-and-safety-of-its-first-generation-oral-pill-norovirus-vaccine-candidate-in-elderly-adults\/","title":{"rendered":"Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults"},"content":{"rendered":"

\nRobust, antigen-specific responses in the nasal cavity following oral administration underscore the efficiency of Vaxart\u2019s oral vaccine platform in generating mucosal antibody responses beyond the site of administration
\n<\/h2>\n
\n

SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) today announced that complete data from the Phase 1b trial of its first-generation oral pill norovirus vaccine candidate in elderly adults (55-80 years) (NCT04854746<\/a>) have been published in Science Translational Medicine<\/em><\/a>. The data, which show strong and durable antibody responses and induction of norovirus-specific antibody and T cell responses, support immunogenicity of the vaccine candidate in a patient population that often has age-related reductions in immune responses to injected vaccines.1,2<\/sup> Norovirus is a highly contagious virus that causes acute gastroenteritis (AGE) and can lead to substantial morbidity in older adults.3<\/sup><\/p>\n

\u201cA key finding of this study evaluating our first-generation oral pill norovirus vaccine candidate in elderly individuals was that the antibody and serum responses observed in these participants were robust and durable, and a cross-study analysis suggested that the observed antibody and cellular responses were independent of age. These findings are encouraging given that older adults have an increased risk of norovirus-related morbidity and may have less robust immune responses following vaccination compared with younger individuals,\u201d said James F. Cummings, MD, Chief Medical Officer at\u00a0Vaxart. \u201cAnother key result was that an orally-administered vaccine can generate potent antibody responses in mucosal tissues outside the gastrointestinal tract, which could have important implications for use of our vaccine platform for norovirus and other indications as well.\u201d<\/p>\n

The Phase 1b study evaluated the safety and immunogenicity of Vaxart\u2019s oral norovirus vaccine candidate in two groups of healthy older adults aged 55-65 and 66-80 years old. The vaccine was administered orally at three dose levels by prime and boost, 28 days apart. Participants were randomized to receive vaccine or placebo at a 2:1 ratio, and 63 volunteers completed the study, which included safety and immunogenicity assessments through day 390.<\/p>\n

Key findings from the study include:<\/p>\n